[go: up one dir, main page]

AU2002251030A1 - Degradation of epothilones and ethynyl substituted epothilones - Google Patents

Degradation of epothilones and ethynyl substituted epothilones

Info

Publication number
AU2002251030A1
AU2002251030A1 AU2002251030A AU2002251030A AU2002251030A1 AU 2002251030 A1 AU2002251030 A1 AU 2002251030A1 AU 2002251030 A AU2002251030 A AU 2002251030A AU 2002251030 A AU2002251030 A AU 2002251030A AU 2002251030 A1 AU2002251030 A1 AU 2002251030A1
Authority
AU
Australia
Prior art keywords
formula
compound
epothilone
scheme
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002251030A
Inventor
Gerhard Hoefle
Usama Karama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Original Assignee
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum fuer Infektionsforschung HZI GmbH filed Critical Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Publication of AU2002251030A1 publication Critical patent/AU2002251030A1/en
Abandoned legal-status Critical Current

Links

Description

Our ref . : 12838-GBF
New International Patent Application
Gesellschaft fuer Biotechnlogische Forschung mbH (GBF)
Degradation of Epothilones
Epothilones of type C and type D belong to the art and are especially characterized by a C=C double bond at positions 12 and 13 and a hydrogen atom at position 12 (type C) or an alkyl group- (type D) .
According to one embodiment the invention concerns a process for a degradation of an epothilone C or an epothilone D, wherein an epothilone C or an epothilone D is subjected to an olefin metathesis in the presence of ethylene and subsequently an optional ester hydrolysis (scheme I) .
According to the invention the epothilone C or D can be a fermentation product.
According to another embodiment the invention concerns a process for the production of an epothilone of formula 9
9 wherein an epothilone of formula 2a (schemes I and II) is converted into compound of formula 3a (scheme II) , the compound of formula 3a is reacted with a compound of formula 6 (which has been formed by reacting a compound of formula 4 with a compound of formula 5; scheme II) to give a compound of formula 7 by esterification (scheme II) , the compound of formula 7 is reacted in the presence of a Grubbs catalyst to give a compound of formula 8a by deprotection (scheme II) , the compound of formula 8a is converted into a compound of formula 8b by deprotection (scheme II) , and compound of formula 8b is converted to a compound of formula 9 by epoxidation (scheme ID •
Alternatively to the reaction sequence depicted in scheme I synthetic intermediates of type 3 may be obtained according to scheme III by
1) cleavage of the lactone of epothilone C or D with e.g. pig liver esterase (PLE) or, after protection of the 3,7-hydroxyl groups, with aqueous base to give 10 (this conversion is described in U.S. Patent Application 09/811,808, March 19, 2001 by BMS/GBF) ,
2) optionally esterification with diazomethane and optionally protection of the 3 , 7-dihydroxyl groups to give 11,
3) olefin metathesis with an excess of an olefin, e.g. ethylene and a ruthenium or molybdenum metathesis catalyst and optionally protection of the 3, 7-dihydroxyl groups to give 3b.
Experimental Part
12,13-seco-Epothilone C (2a):
450 mg of epothilone C (1) (0.95 mmol) were dissolved in 250 mL of dichloromethane, saturated with ethylene and after addition of 60 mg of Grubb's catalyst (PhCHRuCl2 [P (Cy) 3] 2 stirred for 24 hours. After addition of further 60 mg of catalyst and stirring for 24 hours the dark solution was evaporated to dryness and the residue purified by chromatography on silica with the solvent system hexanes/tert . -butylmethylester/methanol 80:20:1. The first fraction contained 360 mg (75 %) of 2a, the second 100 mg (22 %) of recovered starting material 1.
2a: XH-NMR (CDC13) , 300 MHz): δ = 6.95 (s, 19-H) , 6.02 (s, 17- H) , 5.89 - 5.64 (m, 12-H, 13-H), 5.16 - 4.89 (m, 12a-H2, 13a- H2) , 5.37 (t, J = 7 Hz, 15-H) , 4.24 (ddd, J = 10, 3, 3.5 Hz, 3- H) , 3.36 (s, OH), 3.34 (d, J = 8 Hz, 7-H) , 3.25 (dq, J = 1.5, 7 Hz,~8-H), 3.21 (d, J = 3.8 Hz, OH), 2.70 (s, 21-H3) , 2.52 - 2.32 (m, 2-H2, 14-H2), 2.07 (d, J = 1.5 Hz, 16-Me) , 2.05 - 1.95 (m, 11-H2) , 1.8 - 1.1 (m, 6-H, 8-H, 9-H2, 10-H2) , 1.18 (s, 4- Me) , 1.10 (s, 4-Me), 1.04 (d, J = 7 Hz, 6-Me) , 0.83 (d, J = 7 Hz, 8-Me) .
ESI-MS (pos ions) m/z = 506 [M + H+] , CI - MS (NH3 pos . ions) m/z = 506 [M + H+] (22 %) , 380 (100 %) .
3,7-Di- [tert-buthyldimethyl-silyloxy] -4,4, 6, 8-tetramethyl-5- oxo-12-tridecenoic acid (3a)
To 330 mg (0.65 mmol) of 12 , 13-seco-epothilone C (2a) dissolved in 10 mL of THF were added with stirring 0.6 mL of NEt3 and 0.6 mL of tert-butyldimethylsilyltriflate . After one hour the solvent was evaporated in vacuo. The residue was dissolved in 10 mL of THF, 70 mg of LiOH dissolved in 0.5 mL of water were added and the mixture stirred for 16 hours. The solvents were evaporated and the residue distributed between phosphate buffer of pH 5 and ethyl acetate. The organic layer was dried with MgS04 and evaporated to dryness. Preparative HPLC on RP-18 with the solvent system methanol/20 mmol ammonium acetate buffer pH 7 gave 235 mg (67 %) of 3a as colorless viscous oil. Analytical HPLC on Nucleosil RP-18 (260 x 5 mm) solvent system methanol/20 mmol ammonium acetate buffer pH 7, 1 mL/min, light scattering detector: Rt = 5.5 min.
XH-NMR (CDC13, 300 MHz): δ = 5.78 (m, 12-H) , 4.99, 4.92 (m, 13- H2) , 4.39 (dd, J = 6.3, 3.4 Hz, 3-H) , 3.79 (dd, J = 7.2, 2.0 Hz, 7-H) , 3.12 (dq, J = 7.0 Hz, 8-H) , 2.49 (dd, J = 16.5, 3.5 Hz, 2 -Ha) , 2.32 (dd, J = 16.5, 6.2 Hz, 2-Hb) , 1.5 - 1.0 (m, 6- H, 8-H, 9-H2, 10-H2, 11-H2) , 1.2 (s, 4-Me), 1.07 (s, 4-Me) , 1.04 (d, J = 6.9 Hz, 6-Me) , 0.91 (d, J = 7.0 Hz, 8-Me) , 0.89 (s, tBuSi) , 0.88 (s, tBuSi) , 0.09 (s, MeSi) , 0.06 (s, MeSi) , 0.05 (s, 2 MeSi) . ESI - MS (neg. ions) m/z = 541 (M-H) .
4-Bromo-2-methyl-thiazole (4)
1 g (2.05 mmol) 2 , 4-Dibromothiazole was dissolved in 25 mL anhydrous ether and the resulting solution was stirred under N2 atmosphere at - 78°C. To the solution was added n-BuLi (1.1 equivalent, 4.52 mmol, 2.82 mL of 1.6 M solution in hexane) and the stirring was continued for 1 h. To the reaction mixture was then added dropwise a solution of dimethylsulfate 1.16 mL (12.34 mmol) in 1 mL ether. After stirring for 4 h at -78°C the reaction mixture was allowed to warm to room temperature and stirred for 14 h. The reaction mixture was diluted with a saturated solution of NaHC03 (10 mL) . The aqueous layer was extracted with ether and the combined organic extracts were washed with a brine and dried over MgS04. Concentration under vacuum, and flash column chromatography (silica gel, 10:1 petroleum ether/ethyl acetate), yielded 0.52 g (70.6%) a yellow oil.
IR (KBr) : 3122, 2923, 1485, 1441, 1252, 1178, 1085887, 834 cm-1.
XH-NMR (CDC13, 400 MHz) : δ = 7.02 (s, 1H) , 2.71 (s, 3H) . 13C-NMR (CDCI3, 100.6 MHz) : δ = 167.31, 124.18, 116.11, 19.40. EI-MS (70 eV) : m/z (%) : 179 (93) [M+2H]+, 177 (100) [M+H]+, 169 (30) , 164 (20) , 159 (15) . HRMS (El) : calcd for C4H4BrNS 176.9251, found 176.9248
1- (2-methyl-thiazol-4-yl) -hex-5-en-l-yn-3-ol (6)
480 mg (2.68 mmol) 4-Bromo-2-methyl-thiazole (4) in 4 mL Et3N was added to 131 mg (0.187 mmol) PdCl2(PPh3)2 and the suspension was stirred 15 minutes under N2 atmosphere at room temperature, then 117 mg ( 0.614 mmol) Cul was added under N2 atmosphere followed by dropwise addition of 283 mg alcohol 5 (A.B. Smith, III et al . JACS 120, 3935-3948 (1998)) in 1 mL Et3N. The mixture was stirred for 15 minutes at room temperature and heated to 80°C for 6 h. Concentration under vacuum, and flash column chromatography (silica gel, 3:2 petroleum ether/ethyl acetate), yielded 0.29 g (56 %) a yellow oil. [α] = - 29.1 (c= 1 in chloroform)
IR (KBr) : 3386, 3142, 2924, 1641, 1501, 1435, 1286, 1194, 1041, 993, 918 cm"1.
^Η- MR (CDCI3, 400 MHz) : δ = 7.26 (s, 1H) , 5.98-5.88 (m, 1 H) ,
5.23-5.16 (m, 2H) , 4.62 ( dd, J= 11.9, 5.8 Hz, 1H) , 2.68 (3H,
S) , 2.58-2.54 (2H, m) , 2.39 (d J= 6.1Hz, 1H, OH)
13C-NMR (CDC13, 75.5 MHz) : δ = 165.77, 136.20, 133.09, 122.48,
118.85, 89.53, 79.04, 61.84, 41.87, 19.10.
DCI-MS (NH3) : 211 [M+NH4 +] , 194 [M+H+] .
(IS) -1- [ (2-Methyl-thiazole-4-yl) -1-ethynyl] -3-butenyl (2S,6R,7S,8S) -3,7-di- [tert-butyldimethylsiloxy] -4,4,6,8- tetramethyl-5-oxo-12-tridecenoate (7)
99 mg (0.478 mmoDDCC was added at 0°C to a solution of acid 200 mg (0.368 mmol), alcohol 79 mg (0.405 mmol) and 12 mg (0.09 mmol) DMAP in 10 mL CH2C12 . The mixture was stirred for 15 min at 0°C and for 16 h at room temperature. Concentration under vacuum, and flash column chromatography (silica gel, 10:1 petroleum ether/ethyl acetate) , yielded 240 mg (91%) a yellow oil .
[α] = - 45.8 (c= 1 in CH2C12)
IR (KBr) : 2929, 2856, 1742, 1697, 1641, 1472, 1253, 989 cm"1.
^-NMR (CDC13, 400 MHz) : δ = 7.28 (s, 1H, thiazole H-5) , 5.91-
5.73 (m, 2H, H-12, H-3') ,
5.58 "(t, "= 6.1Hz, 1H, , H-l'), 5.20-4.90 (m, 4H, H-13, H-4"),
4.38 (dd, J= 6.3, 3.3 Hz, 1H, H-3) , 3.74 (dd, J= 6.8, 2.2 Hz,
1H, H-7) , 3.11 (dq, J= 6.8, 6.8 Hz, 1H, H-6) , 2.67 (s, 3H, thiazole CH3) , 2.60 (t, J= 6.6Hz, 1H, , H-2) , 2.55 (dd, J"= 16.7,
3.5 Hz, 1H, H-2') , 2.29 (dd, J= 17.0, 63 Hz, 1H, H-2') , 2.05-
1.95 (m, 2H, H-11) , 1.47-1.29 (m, 3H, ) 1.17-1.08 (m, 2H) (H-8, H-
9, H-10) , 1.21 (s, 3H, H-22), 1.05 (s, 3H, H-23) , 1.03 (d, J=
6.6Hz, 3H, C6-CH3) , 0.89 (d, J= 6.6Hz, 3H, C8-CH3) , 0.88, 0.87(
2s, 2x9H, OSiC(CH3)3) , 0.089 (s, 3H, OSi(CH3)2) , 0.032, 0.028,
0.024 (3S, 3x3H, OSi(CH3)2) .
13C-NMR (CDC13, 100.6 MHz) : 217.63, 170.84, 165.55, 138.97,
136.08, 132.23, 123.22, 118.91, 114.41, 85.67, 79.97, 73.76,
63.77, 53.38, 45.23, 40.20, 39.09, 38.87, 34.35, 34.00, 30.48,
27.11, 26.26, 26.07, 25.66, 24.97, 23.44, 19.89, 18.55, 17.66,
15.52, -3.61, -3.74, -4.20, -4.59
DCI-MS (NH3) : 735 [M+NH +] , 718 [M+H+] .
HRMS (DCI) : calcd for C39H70N2O5SSi2 735.4622, found 735.4675.
{4S, 7R,8S,9S, 16S) -4,8 -Di - tert-butyldimethylsilyloxy-5 , 5,7,9- tetramethyl- -6- [2- (2-methyl-l, 3-thiazol-4-yl) -1-ethynyl) -1- oxa-13-cyclohexadecen-2, 6-dione, mixture of Z and E isomeres (8a)
To a solution of 190 mg (0.264 mmol) diene 7 in 66 mL CH2C12 was added 44 mg (0.053 mmol) bis (tricyclohexylphosphine)benzylideneruthenium dichloride and the reaction mixture was stirred for 48 h at room temperature. Concentration under vacuum, and flash column chromatography (silica gel, 10:1 petroleum ether/ethyl acetate), yielded 95mg (52%) of a yellow oil.
{4S, 7R, 8S, 9S, 16S) -4 , 8-Dihydroxy-tert-5, 5, 7 , 9-tetra-methyl-1-6- [2- (2-methyl-l,3-thiazol-4-yl) -1-ethynyl) -l-oxa-13- cyclohexadecen-2, 6-dione (8b), mixture of cis and trans isomere
A solution of 95 mg (0.137 mmol) lactone X in 12 mL CH2C12 at - 20°C was treated with 2 mL trifluoroacetic acid, and the mixture was stirred for 2 h at 0°C. After concentration under vacuum, the residue was diluted with EtOAC , washed with saturated NaHC03 solution and dried over MgS0 . Concentration under vacuum, and separation by HPLC (80:20:3 hexane/t-BuOMe/ MeOH) , yielded 27 mg (42 %) of the cis-hydroxy lactone 8b and 27 mg (42 %) of the corresponding trans isomer. [α] = - 123 (c= 1 in CH2C12)
XH-NMR (CDC13, 400 MHz) : δ = 7.30 (s, 1H, H-19) , 5.65 (dd,J= 9.1, 2.9 Hz, 1H, H-15) , 5.55-5.41 (m, 2H, H-12, H-13), 4.20 (dd,J= 10.8, 2.7 Hz, 1H, H-3), 3.67-3.65 (m, 1H, H-7) , 3.12 (dq, ι7= 6.6, 2.0 Hz, 1H, H-6) , 2.88-2.77 (m, 1H, H-14) , 2.70 (s, 3H, H-21) , 2.51 ( dd, J= 15.0Hz, 10.9 Hz, 1H, H-2) , 2.27 (dd,J= 15.2, 2.8 Hz, 1H, H-2), 2.18-2.00 (m, 2H, H-11, H-14), 1.71-1.58 (m, 3H, H-8, H-9, H-10) , 1.32 (s, 3H, H-22), 1.30- 1.19 (3H, H-8, H-9, H-10), 1.18 (d, J= 6.7Hz, 3H, H-24), 1.07 (s, 3H, H-23), 0.98 (d, J= 6.9Hz, 3H, H-25)
13C-NMR (CDC13, 75.5 MHz) : δ = 220.81, 169.96, 164.44, 134.16, 134.27, 123.75, 123.00, 86.13, 80.00, 74.38, 72.03, 64.11, 53.31, 41.74, 39.37, 38.71, 32.87, 32.37, 27.63, 27.47, 22.69, 19.18, 18.37, 15.46, 13.70. 16,17-Didehydro-16-desmethyl-epothilone A (9)
To a solution of 27 mg (0.058) of lactone (8b) 4 mL CH2C12 was added dropwise at - 20°C a solution of dimethyl dioxirane in acetone ( 2 equiv) . Stirring was continued for 2 h at - 20°C . Concentration under vacuum, and separation by HPLC (80:20:3 hexane/t-BuOMe/ MeOH) , yielded 17 mg (60 %) of α-epoxide 9 and 9 mg (32 %) of β-epoxide.
α-epoxide
[α] = - 34 (c= 1 in CH2C12)
IR (KBr) : 3453, 2958, 2850, 1744, 1690, 1500, 1467, 1376, 1290, 1261, 1147, 979, 775 cm"1.
13C-NMR (CDC13, 100.6 MHz) : 220.55, 170.19, 166.12, 135.50, 123.28, 85.00, 80.56, 75.12, 73.59, 62.71, 57.17, 53.75, 52.67, 43.68, 38.69, 35.96, 32.67, 29.72, 26.56, 23.63, 21.12, 20.48, 19.16, 17.06, 14.46
EI-MS (70 eV) : m/z (%) : 477(27) [M+H]+, 421 (14) , 389 (19) , 378 (100) , 364 (28) , 346 (27) , 328 (15) .
β-epoxide
13C-NMR (CDC13, 75.5 MHz) : δ = 221.38, 170.03, 166.05,135.70 , 123.28, 85.13, 80.48, 73.24, 73.11, 62.24, 57.14, 55.31, 52.28, 42.89, 38.98, 37.53, 32.40, 31.82, 27.60, 27.01, 23.45, 20.62, 20.36, 16.38, 13.49.

Claims

Our ref . : 12827-GBFNew International Patent ApplicationGesellschaft fuer Biotechnlogische Forschung mbH (GBF)Claims
1. Process for a degradation of an epothilone C or an epothilone D, wherein an epothilone C or an epothilone D is subjected to an olefin metathesis in the presence of ethylene and subsequently an optional ester hydrolysis (scheme I) .
2. Process according to claim 1, wherein the epothilone C or D is a fermentation product.
3. Process for the production of an epothilone of formula 9
wherein (i) an epothilone of formula 2a (schemes I and II) is converted into compound of formula 3a (scheme II) , (ii) the compound of formula 3a is reacted with a compound of formula 6 (which has been formed by reacting a compound of formula 4 with a compound of formula 5; scheme II) to give a compound of formula 7 (scheme
ID, (iii) the compound of formula 7 is reacted in the presence of a Grubbs catalyst to give a compound of formula 8a
(scheme II) , (iv) the compound of formula 8a is converted into a compound of formula 8b (scheme II) , and (v) compound of formula 8b is converted to a compound of formula 9 (scheme II) .
4. Process according to claim 3, wherein at stop (i) first free hydroxy groups are protected and second an ester hydrolysis is carried out.
5. Process according to claim 3, wherein at step (iv) deprotection is carried out in an acidic medium preferably by means of trifluoro acetic acid.
6. Process for the production of a compound of formula 3b
R = H, Methyl
P = H, protecting group e.g. trialkylsilyl, p-methoxybenzyl wherein 3b (i) the lactone group of an epothilone C or an epothilone
D is cleaved, (ii) the cleavage product of formula 10 (scheme III) is optionally subjected to an esterificartion with diazomethane and the 3,7-hydroxy groups are optionally protected to give a compound of formula 11 (scheme III) and (iii) the compound of formula 11 is subjected to an olefin metathesis and the 3,7-hydroxy groups are optionally protected, to give a compound of formula 3b (scheme III) .
7. Process according to claim 6, wherein in step (i) the cleavage is carried out
- with pig liver esterase or
- after protection of the 3,7-hydroxy groups, with an aqueous base .
8. Process according to claim 6, wherein in step (iii) ethylene is used as olefin and/or a ruthenium or molybdenum catalyst is used as metathesis catalyst.
9. Process according to claim 3 or claim 6, wherein the 3,7- hydroxy groups are protected by trialkylsilyl or p-methoxybenzyl .
10. Process according to claim 6, wherein the compound of formula 3b is further processed in accordance to steps (ii) to (v) of claim 3.
11. Compounds of formula 2, 2a, 3, 3a, 3b, 4, 5, 6, 7, 8, 8a, 8b, 9, 10 and 11, obtainable according to a process according to one or more of the preceding claims .
AU2002251030A 2001-02-27 2002-02-27 Degradation of epothilones and ethynyl substituted epothilones Abandoned AU2002251030A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01104448.4 2001-02-27

Publications (1)

Publication Number Publication Date
AU2002251030A1 true AU2002251030A1 (en) 2002-09-24

Family

ID=

Similar Documents

Publication Publication Date Title
US6288237B1 (en) Epothilons C and D, preparation and compositions
RU2201932C2 (en) Epotilons modified by by-side chain
Schinzer et al. Total synthesis of (−)‐epothilone A
US7759375B2 (en) Epothilones C, D, E, and F, preparation and compositions
Nicolaou et al. Total Synthesis of 16‐Desmethylepothilone B, Epothilone B10, Epothilone F, and Related Side Chain Modified Epothilone B Analogues
US6660758B1 (en) Epothilone analogs
AU5757798A (en) Epothilone analogs
EP1564217B1 (en) Process for the production of epothilones
AU2002251030A1 (en) Degradation of epothilones and ethynyl substituted epothilones
Zhang et al. Recent progress in the synthesis of epothilones
US8030503B2 (en) Process for the preparation of epothilones
US6376230B1 (en) Stereoselective process for producing intermediates of cryptophycins
EP0987268B1 (en) Pharmaceutical agents containing epothilone A-N-oxide and/or epothilone B-N-oxide
EP1127055A2 (en) Stereoselective process for producing cryptophycins